foreign operational Revenue about guidance and delivered of third discuss COVID-related in And high the XX% also quarter joining good came us growth of you, another in work. exchange diluted X.X% the you our to results. Thank above strong adjusted delivered results.
IQVIA and for impact excluding EPS. representing Kerri, Thank of quarter we growth, range, our morning, everyone. end today
launching are to businesses the clients as on critical commercial executing for programs. improve our our new expected, environment drugs short-cycle we continues and As
with since growth second trajectory the the in as the revenue mid-single-digit TAS range. TAS accelerated expect for fact, the the subsegments. In that now all our growth anticipated growth high at in over we year-over-year, end we for growth had beginning of year This X% And year. reaffirms QX of to half
On aggressive side, calls. the earnings None near-term continues the as been know, environment new, you competitive be discussing is tougher and but clinical this choppy pricing negotiations. prior been market facing as of we've we've in to
program of in that a and trend expect been the we over their the ago a be the the as years and quarter. re-prioritizing fourth case has started again Additionally, been IRA result cancellations, level large of leading portfolios X.X to continuing, higher-than-normal pharma to with this has this
know, But you it more to On have levels take the translate funding year RFP for translate this funding improved. as this awards. EBP does and to even time into actual time into side, flows
was business X.XX, for book-to-bill book-to-bill in the be Our futility million trial. included drug the but impacted substantial to cancellation, due excluding approximately our cancellation bookings quarter would $XXX reported The X quarterly new net that a the by that specific net X.XX.
issues. share September, more already guidance, late were due that in need that start-up in mega X short-term Lastly, studies client-related to clients Ron will of to and notified us delay X logistics phase affects their about This later. our
business some demand of to it's strength our The share and long-cycle challenges, important is short-term our metrics business. seeing. in remember like these through navigate CRO resilience business.
I'd a details us the confidence give we to are what that of we While
To consolidate date, strategic year large pharma successfully their to pharma partnerships. Firstly, reevaluate partnership. as been you running large strategic single renewed this may know, have have companies we and every many processes
our two, gain because their these was $XX of the that And it is that added programs reached scope more and share in displaced than are Biotech opportunities One about in by represents a to relationships, have which opens of strategic partnerships means team. clients. X RBS to pharma In according growth their new wallet funding aspects for partnerships. our over pharma EBP in greater we've expanded large in XX% performance funding this and incumbents to the up over strategic large $XX successful IQVIA. biotech fact, with year-over-year. existing In quarter billion, dozen us the future consolidated that customers world, year-to-date, in billion trust There the clients reaffirmed half funding BioWorld, have
quarter, of the that Fifth up X% remains observation, of end the our it earlier, XX-month it year. growth our I new and as next compared represents months before years Four, in to year-over-year. a our and reached translates healthy record of backlog funding prior a Now year book-to-bill X.XX. at at billion does from time, is Three, take revenue actual take backlog remarked X.X% trailing could the $XX.X XX again, that to X.X awards.
quarterly our in and And the all pipeline RFP digits customer it low compared grew the the double we to in that And is good. finally, qualified increasing year-over-year. continued is year. Our quarter same trend mid-single segments, the half, prior flow digits saw across overall first up
to that in been I just environments, pipeline digits. that stronger in be sometimes qualified high double up market should balanced, Now has out point
X.X% the at growth. excluding periods, and for both results the at which is under the the work COVID-related a constant on Compared X.X% quarter. currency top X% last and currency. for to constant organic grew year, we grew quarter Revenue from basis about turn of reported line to let's X.X% just Now
increased X.X% XX quarter in margin of EBITDA cost resulted Third bps that ongoing and expansion. and management and discipline, growth revenue driven by adjusted
of like of and diluted to increased year-over-year. share as few $X.XX is EPS I'd Third a highlights quarter business $X XX.X% adjusted practice activity. our
for clinical dedicated a as We're by to and Central strategic where public to XX for outbreak IQVIA awarded Lab company expertise, a these provider groundbreaking XX as continue X clinical our for III home therapeutic can were vendor a study cell studies and to key for several therapies oncology, a quarter, know, escalation won to an recently trial without in critical to partner access selection to several third for provide and area to biotech vaccines our offerings. AI-enabled dose gene project who a technology. and Sub-Saharan biotech single for and cancer, Within a that multiple targeting client IQVIA after a is, to technology we continue trial sponsors in we for partnership to unmet well expertise management of a as as services to to existing for III extension the Phase multiple new leveraging addressing our Mpox VCT Let We in the our setup ability early awards, run patients top monitoring, as selected well me market, only large selected pharma with sites trial Africa client to progressed quarter, in capacity both clinical bring leading IQVIA large aims immunotherapy In III in program sites A Across therapeutic cardiovascular Phase leader client with a first-line by a differentiate the expansion a significant large and with global prostate combinations. to solutions. Within biosimilar pharma start preferred secured myeloma. study cell RMBS, conduct for to Phase as for medical our FSP region first conduct in renal in having clinical designs, in health differentiate teams a customer client offer the client global trial the reoccurring lymphatic metabolic offering. increase our VCT streamlining expedite you we global manage with run a we to have the via fact, site phase myeloma sign-on carcinoma technology, data selected expand top biotech engagements technology in launched which platform. multiple needs. with including solutions pharma a biotech study parties. A and This for clinical deliver biosimilar industry, cancer the the our U.S. system. biotech at clients. partnership were
with preparedness the several SETI, Marburg greater responded outbreak XX% than Rwandan institutes to of in and of fever the an innovations in fatality and government Finally, the partnership at the Rwanda epidemic IQVIA for end coalition with virus, the a hemorrhagic September.
the of Our X patient organizations collaborated with mobilize first an and to within dose the vaccination investigational outbreak. days
to TAS. Moving
had is even is recovering you our we to than continue One differentiating better strides our results, offerings. in make As area across forecasted. AI capabilities great in we the building from business saw
The this This sales multiyear our across system quick a an with generative countries. schizophrenia integrated contract OCE, solution to conversational allows new You seen and which secured and orchestrated designed a efficiency new we a ask to questions through provide AI-enabled funding pharma and enhances client's the decisions European and launched assistant, optimize contract engages an insights to a contract by based top a XX have science examples client intelligent X to solution client. on AI sales interface. alerts American frequency. by IQVIA top with incumbent the IQVIA's pharma share countries payer weekly A validation awarded their accurate, evidence-based X real-time affairs action large IQVIA key activities incumbent comprehensive treatment. and complex franchises. life the through offering customers offerings. a health will support co-pay on shows targeting with pharma for This clients and IQVIA AI of provide will real tool drive couple and industry. provides in multiyear support deal the business for daily new powerful GLP-X launch voice based deliver segment, This analytics, offering with users X reimbursement loss pharma user-friendly clients IQVIA includes better support health receive team AIS market. the contract the improve and top the privacy interactions on activities therapeutic to to a X The top awarded AI recently IQVIA, displaced best And is optimizes reliable weight medications solution care-grade KOLs models. is patient XX scientific to IQVIA A IQVIA engagement X a was expert that all time. reliable reps care for built North clients IQVIA engagement and outcomes. HCP inputs North a one IQVIA enable biotech pharma based in rep in of answers and top core versus analysis as awarded a access case, trademark and in approach output on improve oncology The enables assets demanded world next HCPs multiyear for to the selected areas new clients the HCPs. of large in of of women's by safeguards prelaunch enhances which we the health extensive clinical is American workflow experts health real fully clients to to for detailed client that medical provide connected across engagement to
Finally, in to turn like I'd more to Durham, to it of for Investor Carolina. campus performance, IQVIA on and Ron over the XXth our before details scheduled on which headquarters for our invite has I December been you North Day, our financial
be Relations on our Our available Event team additional portal. Ron? will already information available details. to investor is provide logistical Investor
